Economic and QOL evidence scarce in mantle cell lymphoma
- PDF / 167,316 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 41 Downloads / 170 Views
1
Economic and QOL evidence scarce in mantle cell lymphoma The burden associated with mantle cell lymphoma (MCL) is substantial, but the published economic and healthrelated QOL (HRQOL) evidence relating to MCL is scarce. These are the main findings of a systematic literature review that evaluated the evidence relating to economic evaluations, resource use and costs, as well as HRQOL in patients with MCL.* The review identified 11 economic evaluations, 7 studies that assessed costs and/or resource use, and only 5 studies reporting scores or utilities for specified HRQOL instruments. All studies were published between 2007 and 2018. Most of the economic evaluations were cost-effectiveness and/or cost-utility analyses, conducted using a Markov model. Four of the economic evaluations focused on first-line treatments and 7 modelled treatments in the relapsed/ refractory setting, where patients received chemo-immunotherapy or targeted agents (acalabrutinib, bortezomib, ibrutinib, lenalidomide, temsirolimus or venetoclax). In 2 of the 7 studies that assessed costs and/or resource use, adverse events were reported as key drivers of increased resource use and costs. Only 2 of the 7 studies reported direct healthcare costs. All 5 HRQOL studies used cancer-specific instruments, but only one study, the multinational MCL3001 trial of ibrutinib versus temsirolimus in the relapsed/refractory setting, reported preference-based utilities in patients with MCL. This study showed HRQOL improvement with ibrutinib, which was correlated with clinical response. "The evidence relating to MCL in the published literature is scarce; however, the available evidence highlights a critical unmet need for new agents that improve outcomes in this patient population," conclude the researchers. * The study was funded by Janssen. Monga N, et al. Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. PharmacoEconomics-Open : 29 Sep 2020. Available from: URL: https://doi.org/10.1007/s41669-020-00231-w
1173-5503/20/0864-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803506586
PharmacoEconomics & Outcomes News 17 Oct 2020 No. 864
Data Loading...
